Skip to main content
search
Poster

Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA

Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA

For bispecific T-cell engagers (TCEs) in solid tumors, translating from preclinical to clinical exposures results in inconsistent predictions and dose discrepancies of up to 3 orders of magnitude. Using in vitro or mouse trimer per target cell translation results in predictions closer to the pharmacologically active dose.

Access this resource